Evidence map›Paper›PMID 36360292›Full record

ArticleGenes2022

Role of Fiber Shaft Length in Tumor Targeting with Ad5/3 Vectors.

Maximilian Richter, Hongjie Wang, André Lieber

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maximilian RichterDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Hongjie WangDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
André LieberDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
University of Washington Medical Center · US

Funding

Vaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1M
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPYR01CA080192 · NCI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 1999 to 2009
$2.0M
Evaluation of vectors based on group B adenovirusesR01HL078836 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2005 to 2009
$1.4M
NCI NIH HHS P50 CA083636NCI NIH HHS R01 CA080192NIH HHS P50 CA83636NIH HHS R01 CA080192NIH HHS R01 HLA078836
6 · The paper itself

Abstract

Desmoglein 2 (DSG2) is overexpressed in many epithelial cancers and therefore represents a target receptor for oncolytic viruses, including Ad5/3-based viruses. For most Ad serotypes, the receptor-binding fiber is composed of tail, shaft, and knob domains. Here, we investigated the role of the fiber shaft in Ad5/3 tumor transduction in vitro and in human DSG2-transgenic mice carrying human DSG2

Indexed as

Adenoviruses, HumanNeoplasmsAnimalsCapsid ProteinsGenetic VectorsHumansLuciferasesMiceCapsid ProteinsLuciferasescoagulation factor Xdesmoglein 2oncolytic virusserotype 3

Identifiers

PMID36360292
PMCPMC9690795
OpenAlexW4308507710

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.